tag:blogger.com,1999:blog-39108587342081363872012-01-16T04:45:07.321-08:00hkitty47http://www.blogger.com/profile/03574334240792059059noreply@blogger.comBlogger11100tag:blogger.com,1999:blog-3910858734208136387.post-55157814499381329662007-06-07T07:35:00.001-07:002007-06-07T07:35:39.953-07:00By Robert Simison and Elizabeth Lopatto<br /><br />June 7 (Bloomberg) -- Biomet Inc., a maker of orthopedic implants, agreed to a sweetened $11.4 billion buyout offer from private equity firms after a lower bid was criticized by one of the biggest <a href="http://www.lefthit.com/tag/%E0%B9%80%E0%B8%81%E0%B8%A1%E0%B9%81%E0%B8%95%E0%B9%88%E0%B8%87%E0%B8%95%E0%B8%B1%E0%B8%A7%E0%B8%99%E0%B8%B1%E0%B8%81%E0%B8%A3%E0%B9%89%E0%B8%AD%E0%B8%87%0D.html">shareholders</a> and an advisory firm. <br /><br />The new $46-a-share proposal is 4.5 percent higher than the $44 that Blackstone Group LP, Kohlberg Kravis Roberts & Co., TPG, and the private-equity arm of Goldman Sachs Group Inc. had made. Biomet, based in Warsaw, Indiana, said in a statement today that it canceled a vote set for tomorrow on the old bid. <br /><br />The buying group will start a tender offer by June 14, Biomet said. The increased bid may close a dispute over the company's value set off in December when Biomet accepted the equity group's $10.9 billion offer. Smith & Nephew Plc, Europe's biggest maker of orthopedic devices, said Biomet rejected its higher bid, and Institutional Shareholder Services recommended that investors vote against the transaction.<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/3910858734208136387-5515781449938132966?l=china-in-a-nutshell.blogspot.com' alt='' /></div>hkitty47http://www.blogger.com/profile/03574334240792059059noreply@blogger.com5